Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Inventiva, a clinical stage biopharmaceutical company with expertise in fibrosis, oncology and orphan diseases.

Under the terms of the agreement, which combines the scientific and technical expertise of both companies, BLB will perform cutting-edge research to understand the mechanisms underlying the beneficial effects of Inventiva’s lead compound lanifibranor on liver cirrhosis and portal hypertension. The research plan incorporates different BLB’s models of liver disease, including the unique ExoLiver® platform, to obtain consistent pre-clinical data.

For more information about the services and research developed by BLB please visit